Thursday, April 23, 2009

Announcement to Shareholders Regarding the Annual General Meeting of Shareholders of the Company

We hereby annouce to the Shareholders of PT Kalbe Farma Tbk. (hereinafter referred to as the “Company”) that the Annual General Meeting of Shareholders of the Company (the “Meeting”) will be convened on Thursday, May 14th 2009.

In compliance with the provisions of Article 21 paragraph (2) of the Company’s Articles of Association, an invitation of the Meeting will be advertised in 2 (two) Indonesian daily newspapers, 1 (one) which has a nationwide circulation and 1 (one) which is circulated at the domicile of the Company on April 29th 2009.

Those who reserve the right to attend or be presented in the Meeting are:

  1. The Company’s Shareholders whose names are registered in the Register of Shareholders of the Company on April 28th 2009 not later than 4.00 pm Western Indonesia Time,

  2. For shares in the Collective Custody, only the account holders or their proxies whose names are registered in the account holders or custodian bank at PT Kustodian Sentral Efek Indonesia (“KSEI”) on April 28th 2009 not later than 4.00 pm Western Indonesia Time; and

  3. Holders of KSEI’s securities account in the Collective Custody shall provide List of Shareholders they manage to KSEI to obtain a Written Confirmation For the Meeting (“KTUR”).
    Please be advised that proposals from Shareholders for inclusion in the agendas of the Meeting must be submitted pursuant to the provisions of Article 21 paragraph (6) of the Company’s Articles of Association and received by the Board of Directors at least 7 (seven) days before April 29th 2009.

Jakarta, April 14th 2009

The Board of Directors


Friday, April 03, 2009

TheraCIM drawn attention at Asian Oncology Summit

The inaugural Asian Oncology Summit (AOS) – 2009 was held at Suntec Singapore International Convention & Exhibition Centre, Singapore. AOS major success is to have a partnership with South East Asian Medical Oncology Forum (SEAMOF) to encourage collaboration among oncologists in Southeast Asia. The Summit encompassed a series of plenary lectures covering a variety of haematological and solid cancers. There were additional six parallel suites dedicated to haemato-oncology, head and neck, gastrointestinal, breast, lung, and gynaecological cancer. The summit described the latest clinical needs for oncologists in Asia and offered an opportunity for the exchange ideas and thoughts that will help inform clinical practice. Notable international experts includes Prof Harald zur Hausen (Nobel Laureate) had discussed topics of pertinent clinical relevance.

During AOS, experts in oncology shared their experience how to combat cancer incidences and treatment strategy in various cancer types. It was estimated that 58.8 million people died globally from cancer in 2004 (WHO 2008). In South East Asia, it is estimated that in 2008 there were 1,589,000 incident cases of cancer (758,000 in men and 831,000 in women) and 1,072,000 deaths from cancer (approx 557,000 in men and 515,000 in women). In men, the commonest cancer was lung cancer, followed by oral cancer and in women, cervix and breast cancer were the commonest incident.

A panel of speakers had delivered speech on currently available targeted therapy in combination of conventional treatment, and stratified drug therapy with respect to cancer genetics. Targeted therapy has been encouraging the oncologists in the treatment of haematological and solid tumors. Small molecules (tyrosine kinase inhibitors; TKIs) as well as biologics (monoclonal antibodies; mAb) have been evaluated in different tumors in combination with chemotherapy (CT) and/or radiotherapy (RT). TKIs (gefitinib, imatinib, sorafinib, sunitinib) and mAb (cetuximab, trastuzumab, bevacizumab, nimotuzumab) described therapeutic efficacy in binding to their respective targets and hence improved in response rate to the treatment. Some of the clinical trials with targeted therapy have shown an increase in progression-free survival (PFS) as well as overall survival (OS) rate in cancers such as breast, head and neck etc. However, some of the anti-EGFR agents have been associated with severe toxicity in cancer patients.

During the recent summit, nimotuzumab (TheraCIM) had drawn attention by the oncologists and scientists from different parts of the world for its “affinity-optimizedTM” properties towards EGF receptor. Dr Rikrik Ilyas, director, Innogene-Kalbiotech, Singapore had described the development and therapeutic efficacy of nimotuzumab in treating tumors with high EGFR expression. Nimotuzumab is a humanised monoclonal anti-EGFR antibody with reduced toxicity and immunogenicity, and has been approved for the treatment of nasopharyngeal carcinoma (NPC), SCCHN and glioma. The combination of nimotuzumab and RT has significantly increased overall response rate in patients with NPC and other advanced stage head and neck cancers.

During a satellite symposium organised at AOS by Innogene-Kalbiotech, Prof Mark Vincent from University of Western Ontario, Canada explained that “nimotuzumab efficacy in the treatment of EGFR over-expressed tumors is similar to other anti-EGFR agents, cetuximab and panitumumab. Regarding toxicity, nimotuzumab discriminates cells with respect to EGFR expression by binding preferentially to tumor cells over-expressing EGFR, whereas cetuximab and panitumumab bind to all tissues expressing EGFR. The attachment of nimotuzumab to EGFR required bivalent binding, which occurs more readily when EGFR density is elevated. In contrast, when EGFR density is low, such as in healthy tissue, cetuximab and panitumumab continued to interact strongly with EGFR through monovalent binding, while nimotuzumab monovalent binding was transient thus sparing healthy tissues and avoiding the associated severe toxicities. An “affinity-optimizedTM” property of nimotuzumab has shown superior safety profile while exhibiting similar therapeutic efficacy compared to other anti-EGFR mAbs. Severe hypomagnesemia and skin rash is common with the treatment of cetuximab and panitumamab. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer has been reported”.

A positive relation between the presence and severity of treatment-related rash and survival has been consistently observed with all ant-EGFR agents approved for clinical use. These findings suggest that rash may be a useful surrogate marker of successful EGFR inhibition and clinical benefit and therefore of possible use in identifying patients most likely to benefit from therapy, as well as to guide dose adjustments. However, absence of skin rash with the treatment of nimotuzumab makes it a unique therapeutic agent among the class of anti-EGFR mAb.

In a statement given by Prof Randolph HJ, UCLA “the rash is not only unsightly but is painful and can lead to serious infections. I have had patients require urgent surgical drainage of abscesses related to EGFR rashes. EGFR inhibitor with anticancer activity, but without skin toxicity, would be a great advance for patients”

Nimotuzumab has therefore emerged as a promising therapeutic option for patients with advanced epithelial tumours.

The second Asian Oncology Summit being planned to host at Bali, Indonesia (April 9-11, 2010).

Tuesday, March 31, 2009

PT Kalbe Farma Tbk, grows 12,5% in 2008

Based on Audited Consolidated Financial Statements for the Year Ended on December 31, 2008, PT Kalbe Farma Tbk. and subsidiaries (“The Company”) has achieved net sales of Rp 7.9 Trillion, 12.5% higher compared to Rp 7.0 Trillion in 2007.

The Company’s gross profit reached Rp 3.8 Trillion in 2008, an increase of 7.1% compared to the previous year figure. Due to increase of raw material prices and depreciation of Rupiah against USD, the Company’s gross profit margin has declined to 48.3% from the the previous year figure of 50.7%.

The Company’s operating expenses in 2008 was Rp 2.7 Trillion, or 9.9% higher than the previous year. The largest component of operating expenses was selling expenses of Rp 2.1 Trillion, followed by general and administration expenses of Rp 453 Billion and research and development expenses of Rp 54 Billion. Operating expenses ratio to net sales decreased 0.8% to 33.8% in 2008 compared to 34.6% in 2007.

In 2008, the Company was able to maintain its net income amounting to Rp 707 Billion, an increase of 0.2% compared to Rp 706 Billion in 2007.

The details of each Division performance are as follows:

* Prescription Pharmaceuticals Division, as the main business division of the Company, contributed 27.1% of the total net sales. In 2008, the division reported net sales of Rp 2,131 Billion, 18.0% higher than the previous year.
* Consumer Health Division net sales contributed 20,9% of the total net sales. The division reported net sales of Rp 1,648 Billion. As sales of Energy Drink has not yet recovered in 2008, this division net sales has been down by 11.2% compared to that of previous year.
* Nutritionals Division, the Company’s fastest growing division, contributed 24.5% of the total net sales. This division has successfully achieved its net sales of Rp 1,927 Billion or grew 20.5% compared to Rp 1,600 Billion in 2007.
* Distribution and Packaging Division also made significant contribution to total net sales at 27.5%. This division successfully reported net sales of Rp 2,170 Billion with the highest sales growth of 24.5% in 2008 compared to the previous year.

At the end of 2008, the Company increased its net income per share to Rp 72, grew 2.9% compared to Rp 70 in 2007.

This information will be available on the Company’s website at or for further information please contact:

Vidjongtius / Corporate Secretary
PT Kalbe Farma Tbk.
Gedung KALBE
Jl. Let. Jend. Suprapto Kav. 4
Cempaka Putih – Jakarta
Phone: (021) 428-73688
Fax : (021) 428-73678
Email :


Tuesday, October 21, 2008

RISTEK - Kalbe Science Awards 2008 : The Finalists

Indonesia is one nation that is abundant in its nature wealth. Many flora and fauna have been traditionally used for health care to treat various health disorder / disease in the its population. Unfortunately, although there have been already so many research done, there are still lack of effort in coordinating the research activities to make the potential become reality. - Meanwhile, research on medicinal plants from Indonesian origin and other advanced & applicable medical research for Indonesian people are mostly done by scientists from outside Indonesia. On the other side, there are so many potential Indonesian scientists having plenty of intellectual resources, including in medical research field. However, many of the Indonesian scientists often carried out the research that was for academic purpose only. Once they have obtained a degree, the research results are stored neatly in a table or cabinet.

To overcome the gap between the scientists and the industries (in this case, the pharmaceutical industry), the State Ministry of Research and Technolgy Republic of Indonesia (RISTEK) co-operates with the biggest pharmaceutical company in South-East Asian, Kalbe Farma, held the award for the scientists . It's called Ristek-Kalbe Science Awards 2008.

This competition is looking for results of the medical related research in the field of:

  • pharmaceutical raw materials obtained by applying phytochemistry, biotechnolgy, and medicinal chemistry
  • pharmaceutical dosage forms by applying pharmaceutical technology
  • medical diagnostics
  • health food

There are two (2) categories for these awards:

  1. Young Scientist Awards, seeking for one (1) awardee (winner) with IDR 50,000,000 prize
  2. Best Research Awards, seeking for three (3) awardees with IDR 50,000,000, 30,000,000 and 15,000,000 prizes

The interest of researcher was high, reflected by hundreds of papers that have been submitted.

Below is the finalist from the 2 categories (in alphabetical order) :

10 Best Research finalists :

  • Akhmad Kharis Nugroho, M.Si., Apt - Bagian Farmasetika Fakultas Farmasi UGM
  • Agus Zainal Arifin, S.Kom., M.Kom - Institut Teknologi Sepuluh November, Surabaya
  • Arief Budi Witarto - Puslit Bioteknologi LIPI Cibinong
  • Heni Rachmawati, Apt., M.Si - Sekolah Farmasi ITB
  • Khie Khiong, S.Si., M.Si., M.Pharm. Sc., Ph.D - Divisi Imunologi Puslit Ilmu Kedokteran (PPIK), FK Maranatha
  • Maggy Thenawidjaja Suhartono, Prof. - Institut Pertanian Bogor
  • Maria Immaculata Iwo, M.Si., Apt. - Sekolah Farmasi ITB
  • Ronny Martien, Dr.rer.nat., M.Si - Fakultas Farmasi, Universitas Gadjah Mada
  • Sukmadjaja Asyarie, Dr. - Sekolah Farmasi ITB
  • Sunu Budhi Rahardjo, dr. Ph. D - Divisi Litbang PJN Harapan Kita

5 Young Scientist finalists :

  • Akhmad Kharis Nugroho Dr., M.Si Apt. - Fakultas Farmasi UGM
  • Heni Rachmawati, Dr. Apt., M.Si - Sekolah Farmasi ITB
  • I. Sahidin, Dr. M.Si - Jurusan Kimia, Fakultas MIPA Universitas Haluoleo
  • Supangat dr. M. Kes Ph.D - Fakultas Kedokteran Universitas Jember
  • Tri Agus Siswoyo, M. Agr., Ph.D - Fakultas Pertanian Universitas Jember


Wednesday, September 17, 2008

Announcement Of Resolution Of Extraordinary General Meeting Of Shareholders PT KALBE FARMA Tbk. (“Company”)

It is hereby announced to all shareholders of PT Kalbe Farma Tbk. (hereafter referred to as “the Company”), that the Company’s Extraordinary General Meeting of Shareholders (EGMS) held on Wednesday, 17 September 2008 was declared to be legally authorized to make decision as the EGMS was attended by shareholders representing at least 2/3 (two thirds) of the total shares with lawful voting rights and approved by at least 2/3 (two third) of the total votes lawfully cast at the meeting.

EGMS has adapted resolutions which are mainly as follows:

1. Resolved to approve that the Company shall execute Shares Buy Back Phase II on the terms and conditions as follows.

a.the Shares Buy Back Phase II shall be implemented by the Company after the date of EGMS and shall be executed from time to time in 18 (eighteen) months starting from the date from the date of EGMS;

b.the total number of shares to be repurchased shall not exceed 5,1 % of the total number of shares issued by the Company up to the date of EGMS, or a maximum of 518.339.442 shares of the total number of shares issued and fully paid by the Company, or a total of shares;

c.the funds for executing repurchasing shares (inclusive of transaction costs, broker fees, and other expenses related to the Shares Buy Back Phase II) shall be charged against the Company’s unappropriated retained earnings, provided that the fund shall not exceed Rp. 419.855.000.000,00 including all expenses in connection with preparation of the Company’s Shares Buy Back Program; and

d.the Shares Buy Back Phase II shall be executed on the terms and conditions and according to the procedures publised in :

i.“Information to Shareholders in Relation to the Proposed Plan To Conduct a Second Buy Back of Shares of PT Kalbe Farma Tbk.” announced in advertisements in daily newspapers Bisnis Indonesia and Investor Daily Indonesia, all dated 15 August 2008 and 15 September 2008 as previously disclosed above; also

ii. The provisions of the prevailing statutory regulations. Repurchased shares shall be treated as the treasury stocks and might be sold if the price has increased in such a manner that upon the Company’s consideration it shall bring gain to the Company and shall not be resold to the Company’s employees under ESOP and/or MSOP program. ratify and approve the appointment of institution and supporting professionals which have been appointed by the Company in connection with the Shares Buy Back Phase II, including the appointment of PT. Danareksa Sekuritas to act as the Security Trading Broker in the execution of shares repurchasing in the stock market.

2. Resolved to grant authority to the Company’s Board of Director to take all and any actions whatsoever required by of the prevailing statutory regulations, including but not limited to:
i.determine the purchase price of shares buy back; and
ii.determine the selling price of the repurchased shares.


Monday, March 31, 2008

PT. Kalbe Farma Tbk. Announced 2007 Full Year Audited Results

JAKARTA, Indonesia – March 31, 2008 – PT Kalbe Farma Tbk. (“Kalbe”) released full year 2007 audited report.
Kalbe has recorded revenue of IDR 7.00 trillion or an increase of 15.3% compared to the revenue of IDR 6.07 trillion in 2006. Kalbe’s growth in 2007 had exceeded the growth of national pharmaceutical industry.

The details of each Division’s performance are as follows:

  • Consumer Health DivisionThis Division consists of 3 sub-divisions i.e. Nutritional, Over-the-Counter and Energy Drink. In 2007, this Division recorded revenue of IDR 3.46 trillion or increase of 9.3% compared to IDR 3.16 trillion recorded in 2006, with the largest contribution and highest growth from Nutritional.
  • Prescription Pharmaceutical DivisionThis Division contributed 25.8% to the total consolidated sales in 2007 and recorded revenue of IDR 1.81 trillion or 24.0% higher than IDR 1.46 trillion in 2006. Kalbe had successfully integrated its Marketing Department in 2006 and the benefit had been realized in 2007.
  • Distribution and Packaging DivisionThis Division contributed 24.9% to total consolidated revenue and recorded third parties’ revenue of IDR 1.74 trillion in 2007, 20.0% higher than recorded revenue of IDR 1.45 trillion in 2006. This good growth was due to the new principals acquired.

Kalbe recorded gross profit of IDR 3.55 trillion or 14.6% higher compared to IDR 3.10 trillion in 2006. Gross profit margin decreased from 51.0% of Net Sales last year to 50.7% of Net Sales this year. This is due to the price increase of raw materials and changes of Kalbe’s business portfolio.

Operating expenses in 2007 was IDR 2.42 trillion or increased by 19.5% compared to IDR 2.03 trillion in 2006. The increase in operating expenses was due to increase in marketing activities to maintain and increase market share of Kalbe’s product, increase in transportation and delivery costs in Distribution Division and increase in research and development expenses. Kalbe has always made efforts to optimize its expenses in line with its sales growth.

Operating Profit reached IDR 1.13 trillion which was 5.4% higher than IDR 1.07 trillion recorded in 2006. Operating profit ratio decreased from 17.6% of Net Sales in 2006 to become 16.1% of Net Sales this year.

The Company posted net profit of IDR 706 billion or 4.3% higher than IDR 677 billion recorded in 2006.

With regards to the share buy-back programs, up to March 27, 2008, Kalbe has bought back 327.975.500 shares with total transaction of IDR 386.090.222.969.

This information will be available on Kalbe’s website at or for further information please contact:
Vidjongtius / Corporate Secretary
PT Kalbe Farma Tbk.
KALBE Building
Let. Jend. Suprapto Kav. 4
Cempaka Putih – Jakarta
Indonesia Phone : (6221) 428-73688
Faximile: (6221) 428-73678
Email :

Monday, February 11, 2008

Kalbe Collaborates With IBM to Build Green Data Center and Reduce Energy Consumption

IBM (NYSE: IBM) and Kalbe today announced a collaborative effort to build a new energy efficient "green data center" and undergo a major data center consolidation project, in order to meet Kalbe's technology requirements of its expanding business, while simultaneously saving energy.

A leading pharmaceutical and health company in Indonesia, Kalbe is teaming with IBM to deploy data center consolidation with an explicit goal of reducing energy consumption as well as reducing information technology (IT) maintenance and space in its own data center facilities across Jakarta. IBM will help Kalbe to consolidate five data centers from its current 13 existing data centers during the initial phase.

In addition, IBM will install a green data center on a site of 5,048 square feet. Other site and facilities services and server services to be implemented include data center strategy, data center design, server and storage integration, relocation planning, project management, infrastructure equipment sourcing, installation services and management, data center testing and startup management."

Kalbe is expanding its business into the pharmaceuticals and consumer products segments by developing various products and providing a technology-based electronic distribution system," said Mr. Vidjongtius, information technology director, Kalbe. "In addition to supporting our fast expanding business, we believe the time is right for Kalbe to make a cost- saving and energy-saving purchase. The IBM data center solution allows us to concentrate on continuing to provide the production system and staff with the tools necessary to succeed, while also being environmentally conscious."

"IBM's long history and expertise with data center implementations enabled us to create a solution to save energy and ensure efficient server performance for Kalbe," said Hengkie Kastono, Country Manager, Global Technology Services, IBM Indonesia. "IT departments won't be as concerned with growing energy costs when selecting IBM's data center solutions, which provide an efficient, reliable and secure data center. IBM is making it easier for data center owners to go green with new, more energy efficient technology and services, available as part of IBM's Project Big Green initiative."

IBM has the deep experience to implement the entire solution in eight to 24 weeks, compared to the industry norm which is about 40 weeks. The IBM data center solution integrates power, cooling, rack, management, services and security, allowing for selection of standardized components to create a solution through modular configurations. By using standardized components, the architecture easily scales to meet the evolving needs of the company.

This agreement was signed in the fourth quarter of 2007.

About IBM

Project Big GreenAnnounced in May 2007, Project Big Green is a $1 billion initiative to dramatically reduce energy use by IBM and its clients. The initiative includes new energy efficient IBM products and services and a five step approach to energy efficiency in the data center. If followed, this approach can sharply reduce data center energy consumption, transforming clients' technology infrastructure into "green" data centers and provide energy savings of up to 42 percent for an average data center. The initiative also includes a new global "green team" of more than 850 energy efficiency architects from across IBM. More information about IBM Project Big Green is available at

About Kalbe

PT Kalbe Farma Tbk. ("Kalbe") is one of the leading pharmaceuticals and health products companies in Indonesia and is recognized as the largest regional pharmaceutical company in Southeast Asia. Established in 1966, Kalbe's aim is to assist Indonesians to achieve a higher quality of life by providing them with products that improve their health and well-being. The company's main areas of business activities are the production, distribution, marketing and packaging of pharmaceuticals, health foods and other consumer products. For more information on Kalbe, please visit

(source: CNN Money)